- Global Pharma News & Resources
17-Jun-2021 - 17-Jun-2021

Online Course: Financial Acumen for Executives in Pharma-Biotech-Medtech Licensing by Michelle I Olufeso

Understand key financial and accounting terminology for licensing deals – Anticipate the financial/accounting implications of your decisions when assessing and negotiating licensing deals - Avoid the pitfalls caused by a lack of financial acumen in pharmaceutical licensing.

Why You Should Attend

The Content: Most BusDev & Licensing executives in pharma, biotech or medtech companies have little understanding of accounting implications of the deals they are working on. As a result, when the deals are signed, the accounting treatment is often contrary to what was expected by the executives. By attending this course, you will be well equipped to pre-determine the accounting treatment to ensure there are no surprises post-deal signing.

The Expert: As Roche’s former Head of Accounting, managing the accounting for all R&D alliances within the Roche Group globally, Michelle experienced firsthand the implications of a lack of understanding of accounting principles across functions involved in deal making. Her passion for inspiring others towards excellence led her to head the Roche Diploma in Accounting (RDA) trainings (Basic and Advanced), to develop training materials and to actively facilitate workshops worldwide. Her roles have enhanced her ability to have in-depth discussions with various stakeholders and high-profile professionals, from different countries, having very different backgrounds, across very different accounting and non-accounting topics.

The Financial Acumen for Executives in Pharma-Biotech-Medtech Licensing course is the only available public training course delivered by Michelle I Olufeso on this topic.